Medscape March 14, 2025
Heidi Splete

Oral ensitrelvir was significantly more effective than placebo for preventing COVID-19 infection in uninfected at-risk adults who had exposure to those infected, based on data from a phase 3 trial presented at the 2025 Conference on Retroviruses and Opportunistic Infections.

Ensitrelvir, an oral SARS-CoV-2 3CL protease inhibitor, is approved in Japan for the treatment of mild-to-moderate COVID-19, wrote Akimasa Fukushi, MD, of Shionogi & Co., Ltd, the drug’s Japanese manufacturer, in the study abstract.

The researchers randomized adults who were household contacts of confirmed COVID-19 patients but not yet infected themselves. The modified intent-to-treat population was confirmed negative for COVID-19 at baseline. Participants received ensitrelvir at doses of 375 mg on day 1 and 125 mg on days...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Healthcare System, Pharma / Biotech, Public Health / COVID
CZI’s Priscilla Chan on ‘Virtual Cells’ AI Models to Cure Diseases
Gene Therapy Biotech MeiraGTx Strikes Deal Bringing Generative AI to Pivotal Parkinson’s Trial
Pharma Pulse 3/14/25: Navigating Internal Constraints and Uncertainty, Health Plan Support During Natural Disasters & more
New AI model can estimate a person's true biological age from five drops of blood
Pharma Firms Mallinckrodt and Endo Agree to Merge in $6.7B Cash and Stock Deal

Share This Article